FY2025 EPS Estimate for Kura Oncology Cut by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Brookline Capital Management decreased their FY2025 earnings per share (EPS) estimates for shares of Kura Oncology in a report issued on Wednesday, February 26th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($2.01) per share for the year, down from their previous estimate of ($1.74). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other research firms have also weighed in on KURA. Scotiabank reduced their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Trading Up 1.1 %

Shares of NASDAQ KURA opened at $7.33 on Monday. The business has a 50 day simple moving average of $8.10 and a 200 day simple moving average of $13.64. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $570.01 million, a price-to-earnings ratio of -3.11 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last three months. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in shares of Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after purchasing an additional 1,750 shares during the period. Rhumbline Advisers increased its position in shares of Kura Oncology by 2.0% during the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock valued at $871,000 after purchasing an additional 1,923 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the period. Teacher Retirement System of Texas increased its position in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after purchasing an additional 2,285 shares during the period. Finally, MetLife Investment Management LLC increased its position in shares of Kura Oncology by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock valued at $390,000 after purchasing an additional 2,776 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.